Algert Global LLC Y M Abs Therapeutics, Inc. Transaction History

Algert Global LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$4.86 - $7.23 $86,508 - $128,694	-17,800 Reduced 40.03%	26,670 $145,000
Q2 2023 Aug 14, 2023	BUY	$5.68 - $10.34 $105,932 - $192,841	18,650 Added 72.23%	44,470 $302,000
Q4 2022 Feb 13, 2023	BUY	$3.0 - $15.17 $25,014 - $126,487	8,338 Added 47.69%	25,820 $126,000
Q3 2022 Nov 15, 2022	BUY	$13.96 - $19.67 $40,735 - $57,397	2,918 Added 20.04%	17,482 $252,000
Q2 2022 Aug 15, 2022	BUY	$8.22 - $15.13 $33,291 - $61,276	4,050 Added 38.52%	14,564 $220,000
Q1 2022 May 16, 2022	BUY	$6.55 - $17.42 $68,866 - $183,153	10,514 New	10,514 $125,000

106

24.5M

40.3K

400

Ticker YMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,719,500
Market Cap $487M
Description
Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel antibody based therapeutic products for the treatment of cancer in the United States. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment o...

Get notified when there are updates to the investment portfolio of Algert Global LLC, based on Form 13F filings with the SEC.

Stay updated on Algert Global LLC with notifications on news.